ConductScience.org, home

Paper5289712

Clinical pharmacology of 1-beta-d-arabinofuranosyl cytosine.

Ho DH and 1 other. Clin Pharmacol Ther, 1971. Cited by 377 papers, by iCite.

Cite this record

ConductScience Library. Clinical pharmacology of 1-beta-d-arabinofuranosyl cytosine. Papers, record 5289712. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/5289712

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Clinical pharmacology of 1-beta-d-arabinofuranosyl cytosine.
PubMed
Journal
Clin Pharmacol Ther
PubMed
Year
1971
PubMed
Publication types
Journal Article
PubMed
Citations, by iCite
377
iCite
Relative citation ratio, by iCite
13.5
iCite
Revised in PubMed
2019-05-11
PubMed

Authors2

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Ho DHD H
2Frei E 3rdE

Source PubMed

Download CSV of authors

Topics19

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
Antineoplastic AgentsMajor topic
CytarabineMajor topic
Administration, Oral
Animals
Arabinose
Erythrocytes
Half-Life
Humans
Infusions, Parenteral
Injections, Intravenous
Injections, Spinal
Leukemia L1210
Leukemia, Myeloid
Mice
Neoplasm Transplantation
Nucleosides
Time Factors
Tritium
Uracil

Source PubMed

Download CSV of topics

Cited by76

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 377 citations.

PMIDTitleJournalYearIn PapersSource
37670479Oral cytarabine ocfosfate pharmacokinetics and assessment of leukocyte biomarkers in normal dogs.J Vet Intern Med2023https://conductscience.org/library/papers/37670479PubMed
37363044Theoretical aspects of interaction of the anticancer drug cytarabine with human serum albumin.Struct Chem2023https://conductscience.org/library/papers/37363044PubMed
33328603Optimal dosing of cytarabine in induction and post-remission therapy of acute myeloid leukemia.Leukemia2021https://conductscience.org/library/papers/33328603PubMed
31200562Improving the Brain Delivery of Chemotherapeutic Drugs in Childhood Brain Tumors.Cancers (Basel)2019https://conductscience.org/library/papers/31200562PubMed
31098682A phase 2 study to assess the pharmacokinetics and pharmacodynamics of CPX-351 and its effects on cardiac repolarization in patients with acute leukemias.Cancer Chemother Pharmacol2019https://conductscience.org/library/papers/31098682PubMed
30836199Film interface for drug testing for delivery to cells in culture and in the brain.Acta Biomater2019https://conductscience.org/library/papers/30836199PubMed
30041457Nucleobase and Nucleoside Analogues: Resistance and Re-Sensitisation at the Level of Pharmacokinetics, Pharmacodynamics and Metabolism.Cancers (Basel)2018https://conductscience.org/library/papers/30041457PubMed
26563190High-dose cytarabine salvage therapy for recurrent primary CNS lymphoma.J Neurooncol2016https://conductscience.org/library/papers/26563190PubMed
25713072A metal-containing nucleoside that possesses both therapeutic and diagnostic activity against cancer.J Biol Chem2015https://conductscience.org/library/papers/25713072PubMed
24045660Aerosolised 5-azacytidine suppresses tumour growth and reprogrammes the epigenome in an orthotopic lung cancer model.Br J Cancer2013https://conductscience.org/library/papers/24045660PubMed
23666364High-dose cytarabine (HD araC) in the treatment of leukemias: a review.Curr Hematol Malig Rep2013https://conductscience.org/library/papers/23666364PubMed
20842542Modified nanoprecipitation method for preparation of cytarabine-loaded PLGA nanoparticles.AAPS PharmSciTech2010https://conductscience.org/library/papers/20842542PubMed
20607357High-dose chemotherapy with hematopoietic stem cell transplantation for the treatment of primary central nervous system lymphoma.J Neurooncol2011https://conductscience.org/library/papers/20607357PubMed
19941076PCR-based methods for CDA K27Q and A70T genotyping: genotypes and alleles distribution in a central Italy population.Mol Biol Rep2010https://conductscience.org/library/papers/19941076PubMed
18836794AraU accumulation in patients with renal insufficiency as a potential mechanism for cytarabine neurotoxicity.Int J Hematol2008https://conductscience.org/library/papers/18836794PubMed
16446974Identification of functional single nucleotide polymorphism haplotypes in the cytidine deaminase promoter.Hum Genet2006https://conductscience.org/library/papers/16446974PubMed
15825312Assessment of cytosine arabinoside as an antiviral agent in humans.Antimicrob Agents Chemother1974https://conductscience.org/library/papers/15825312PubMed
11572766
Close correlation of 1-beta-D-arabinofuranosylcytosine 5'-triphosphate, an intracellular active metabolite, to the therapeutic efficacy of N(4)-behenoyl-1-beta-D-arabinofuranosylcytosine therapy for acute myelogenous leukemia.
Jpn J Cancer Res2001https://conductscience.org/library/papers/11572766PubMed
11417472Nucleoside analogues: mechanisms of drug resistance and reversal strategies.Leukemia2001https://conductscience.org/library/papers/11417472PubMed
11376564Monitoring of intracellular 1-beta-D-arabinofuranosylcytosine 5'-triphosphate in 1-beta-D-arabinofuranosylcytosine therapy at low and conventional doses.Jpn J Cancer Res2001https://conductscience.org/library/papers/11376564PubMed

See all 76 cited byDownload CSV of cited by

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • Comments and corrections
  • References
  • Genes
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/5289712

GET https://conductscience.org/api/papers/v1/5289712/cited_by?page=2